FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170045360> ?p ?o ?g. }

• W2170045360 endingPage "2199" @default.
• W2170045360 startingPage "2197" @default.
• W2170045360 abstract "In the last three decades we have made considerable progress in combating breast cancer, and during this time certain lifestyle behaviors have emerged as important modifiable risk factors that play a key role in both the prevention and treatment of this disease. Specifically, consistent observational evidence has shown that women who are obese at breast cancer diagnosis have an approximate 33% higher risk of recurrence and mortality compared with normal-weight women, and being physically active after a breast cancer diagnosis is associated with a 30% to 40% lower risk of breast cancer recurrence and mortality. A growing number of studies have also observed an association between postdiagnosis weight gain and a higher risk of recurrence and mortality, independent of body mass index at diagnosis. However, a major remaining question is whether postdiagnosis weight loss in overweight or obese breast cancer survivors negates this adverse association between obesity and poor prognosis. The article by Goodwin et al that accompanies this editorial adds to the growing body of evidence supporting the benefits of weight loss interventions in overweight breast cancer survivors. Although previous studies have evaluated the feasibility and effectiveness of weight loss interventions in breast cancer survivors, the majority of studies have been small (ie, 100 patients), recruited patients from a single institution, had short study durations, and primarily involved inperson weight loss counseling. Strengths of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) by Goodwin et al included a multicenter recruitment approach, a large sample size, a telephone-based intervention, and a 2-year intervention duration. After enrolling overweight breast cancer survivors receiving adjuvant letrozole into a weight loss intervention versus mail-based delivery of general health information, the researchers observed a significant 5.3% weight loss at 6 months in the weight loss group compared with a 0.7% weight loss in the mail-based group. Although the weight loss observed was statistically significant and sustained (3.6% loss at 2 years in the weight loss group v 0.4% weight loss in the mail-based group), questions remain regarding the impact of this amount of weight loss on breast cancer recurrence and mortality. The original aim of LISA was to examine the impact of weight loss on disease-free survival; however, accrual was terminated after the enrollment of 338 of the 2,150 planned participants because a loss of funding, leaving these clinically important questions unanswered. LISA was coordinated by the Ontario Clinical Oncology Group (OCOG), and the 338 patients were recruited from 16 Canadian and four American centers between 2007 and 2010. The primary eligibility criteria for the study were a body mass index of 24 kg/m or higher and receiving letrozole for hormone receptor–positive breast cancer. The study was funded by a pharmaceutical company, demonstrating a unique partnership between industry and behavioral research that could serve as a model for future collaborations. However, that same partnership imposed limitations on the study, restricting eligibility to women taking a particular aromatase inhibitor (AI). Additionally, the funding for the trial was discontinued prematurely, preventing the study from achieving its primary goal and raising another unanswered question: How can important lifestyle trials with definitive mortality end points best be funded? Given that pharmaceutical companies primarily fund therapeutic trials, with little incentive to fund lifestyle interventions, and given the scarcity of funding from government agencies for large-scale, long-term trials of lifestyle interventions with disease-free survival end points, another option may be to require pharmaceutical companies to include lifestyle interventions as an active comparison arm to drug trials, especially in cases when drug options provide modest benefit, or uptake or adherence to particular medications is low. Most medications have negative adverse effects, and AIs, including letrozole, have been shown to have adverse effects that negatively influence adherence to the medication, resulting in a reduced survival benefit. Recently, exercise has been shown to decrease AI adverse effects, specifically arthralgia, and may in turn improve adherence to AIs and breast cancer recurrence and mortality rates. Future research examining the impact of lifestyle interventions and medications such as AIs, together and separately, would provide critical information on the clinical importance of lifestyle interventions with respect to diseasefree survival, quality of life, and medication adherence. While we await the funding of lifestyle interventions with the primary aim to improve mortality, breast cancer survivors need to be informed about the numerous benefits of maintaining a healthy weight and being physically active. Although improvements in early detection and treatment have increased overall survival rates, many patients are left with long-term adverse effects. Favorable changes in lifestyle habits may prevent or attenuate the negative treatmentassociated adverse effects. However, more than 65% of breast cancer survivors are overweight or obese, with a majority of normal-weight women gaining weight after diagnosis, and fewer than 30% engaging in recommended levels of physical activity. Future research efforts need to focus on developing cost-effective lifestyle interventions that are easy to implement in communities. JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 32 NUMBER 21 JULY 2" @default.
• W2170045360 created "2016-06-24" @default.
• W2170045360 creator A5071456493 @default.
• W2170045360 date "2014-07-20" @default.
• W2170045360 modified "2023-10-16" @default.
• W2170045360 title "Weight Loss Interventions and Breast Cancer Survival: The Time Is Now" @default.
• W2170045360 cites W1577435804 @default.
• W2170045360 cites W1929298742 @default.
• W2170045360 cites W1964016825 @default.
• W2170045360 cites W1974196451 @default.
• W2170045360 cites W1987753117 @default.
• W2170045360 cites W2018272127 @default.
• W2170045360 cites W2051872169 @default.
• W2170045360 cites W2069913012 @default.
• W2170045360 cites W2071003201 @default.
• W2170045360 cites W2071637386 @default.
• W2170045360 cites W2074876140 @default.
• W2170045360 cites W2077899509 @default.
• W2170045360 cites W2082707094 @default.
• W2170045360 cites W2094876308 @default.
• W2170045360 cites W2098094536 @default.
• W2170045360 cites W2099786312 @default.
• W2170045360 cites W2102535994 @default.
• W2170045360 cites W2112395080 @default.
• W2170045360 cites W2132571149 @default.
• W2170045360 cites W2144160519 @default.
• W2170045360 cites W2151335341 @default.
• W2170045360 cites W2153786596 @default.
• W2170045360 cites W2158822657 @default.
• W2170045360 cites W2162897974 @default.
• W2170045360 cites W2171227943 @default.
• W2170045360 cites W4236169968 @default.
• W2170045360 doi "https://doi.org/10.1200/jco.2014.56.4583" @default.
• W2170045360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24934785" @default.
• W2170045360 hasPublicationYear "2014" @default.
• W2170045360 type Work @default.
• W2170045360 sameAs 2170045360 @default.
• W2170045360 citedByCount "13" @default.
• W2170045360 countsByYear W21700453602015 @default.
• W2170045360 countsByYear W21700453602016 @default.
• W2170045360 countsByYear W21700453602017 @default.
• W2170045360 countsByYear W21700453602018 @default.
• W2170045360 countsByYear W21700453602019 @default.
• W2170045360 countsByYear W21700453602021 @default.
• W2170045360 crossrefType "journal-article" @default.
• W2170045360 hasAuthorship W2170045360A5071456493 @default.
• W2170045360 hasBestOaLocation W21700453601 @default.
• W2170045360 hasConcept C121608353 @default.
• W2170045360 hasConcept C126322002 @default.
• W2170045360 hasConcept C143998085 @default.
• W2170045360 hasConcept C511355011 @default.
• W2170045360 hasConcept C530470458 @default.
• W2170045360 hasConcept C544821477 @default.
• W2170045360 hasConcept C71924100 @default.
• W2170045360 hasConceptScore W2170045360C121608353 @default.
• W2170045360 hasConceptScore W2170045360C126322002 @default.
• W2170045360 hasConceptScore W2170045360C143998085 @default.
• W2170045360 hasConceptScore W2170045360C511355011 @default.
• W2170045360 hasConceptScore W2170045360C530470458 @default.
• W2170045360 hasConceptScore W2170045360C544821477 @default.
• W2170045360 hasConceptScore W2170045360C71924100 @default.
• W2170045360 hasIssue "21" @default.
• W2170045360 hasLocation W21700453601 @default.
• W2170045360 hasLocation W21700453602 @default.
• W2170045360 hasOpenAccess W2170045360 @default.
• W2170045360 hasPrimaryLocation W21700453601 @default.
• W2170045360 hasRelatedWork W1957309634 @default.
• W2170045360 hasRelatedWork W2134511672 @default.
• W2170045360 hasRelatedWork W2557359331 @default.
• W2170045360 hasRelatedWork W2796519567 @default.
• W2170045360 hasRelatedWork W2809298000 @default.
• W2170045360 hasRelatedWork W2892677547 @default.
• W2170045360 hasRelatedWork W3045530230 @default.
• W2170045360 hasRelatedWork W3134482477 @default.
• W2170045360 hasRelatedWork W3153348389 @default.
• W2170045360 hasRelatedWork W396194156 @default.
• W2170045360 hasVolume "32" @default.
• W2170045360 isParatext "false" @default.
• W2170045360 isRetracted "false" @default.
• W2170045360 magId "2170045360" @default.
• W2170045360 workType "article" @default.